To date, the commercially available inhibitor of IL-6 receptor, tocilizumab, and a gp130 specific inhibitor, FE999301, are only available for the treatment of autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. Here, IL6ST is linked to autoimmune disease.